Navigation Links
Largest academic-industry collaboration for drug discovery in depression and schizophrenia launched
Date:1/19/2010

An international consortium of scientists, led by H. Lundbeck A/S and King's College London, has launched one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs for schizophrenia and depression.

Novel Methods leading to New Medications in Depression and Schizophrenia (NEWMEDS) is a unique project, bringing together top scientists from academic institutions with a wide range of expertise, and partnering them with nearly all major global drugs companies including AstraZeneca, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutica, Novartis, Orion, Pfizer, Roche, Servier and Wyeth.

Other academic institutions involved are: Karolinska Institutet (Sweden), The University of Cambridge (United Kingdom), Central Institute of Mental Health (Germany), CSIC (Spain), the University of Manchester (United Kingdom) and the Bar Ilan University (Israel). A further two pharmaceutical small and medium-sized enterprises (SME), deCODE (Iceland) and Psynova (United Kingdom) will contribute to the success of NEWMEDS, while the SME GABO:mi (Germany) will be managing the project.

With a wealth of new knowledge and research findings related to schizophrenia and depression emerging every year, it has been hard to take these findings from the bench to the clinic. The researchers believe there to be three major bottlenecks that are holding the field back:

  1. a lack of accurate animal models to guide the drug discovery,
  2. a lack of tools and tests in healthy volunteers that can provide early indication of efficacy; and
  3. the reliance of clinical trials on symptom-based Diagnostic and Statistical Manual categories which inevitably leads to biologically heterogeneous groups of patients. NEWMEDS aims to overcome these limitations with a novel approach to drug discovery and strong collaboration within the consortium.

The main objective of NEWMEDS is to develop new models and methods to enable novel treatments for schizophrenia and depression. The project will focus on developing new animal models which use brain recording and behavioural tests to identify innovative and effective drugs for schizophrenia. The project will develop the hardware and analysis techniques to apply brain imaging, especially MRI and PET imaging to drug development. It will examine how new genetic findings (duplication and deletion or changes in genes) influence the response to various drugs and whether this information can be used to choose the right drug for the right patient. And finally, it will try and develop new approaches for shorter and more efficient trials of new medication trials that may require fewer patients and give faster results.

Dr. Tine Bryan Stensbl, Divisional Director for Discovery Pharmacology Research at H. Lundbeck A/S, Coordinator of the NEWMEDS consortium comments: 'Academia and industry have a long tradition of working together on a one-on-one basis. NEWMEDS embodies a novel collaborative effort where companies join forces and together with academia answer scientific questions in a precompetitive environment that will form the basis of tomorrow's medicines. This joint effort will provide novel insights that undoubtedly will be of the benefit of the patients suffering from schizophrenia and depression.

Professor Dr Shitij Kapur, Leader of the Managing Entity from the Institute of Psychiatry at King's College London comments: 'NEWMEDS is a very timely experiment. While the biology of psychiatry has made remarkable progress, we have been slow in converting that into innovative and new medications. This is a joint challenge for academia and industry. NEWMEDS is a joint response. It is not only scientifically innovative, but, it is also an innovation in creating a cluster of nearly 50 scientists from both sides to work together to achieve a common goal better, safer and more effective medications more quickly.'


'/>"/>

Contact: Melanie Haberstroh
melanie.haberstroh@kcl.ac.uk
44-020-784-83076
King's College London
Source:Eurekalert

Related medicine news :

1. FRCs Tony Perkins Speaks to Rally of Ten Thousand Across from Nations Largest Abortion Facility
2. dLife Connects Largest Online Diabetes Community to Facilitate Aid to Haitian Earthquake Victims Suffering From Diabetes
3. Dr. Robert D. Willix Jr. M.D., CEO and CMO of Cenegenics(R) Medical Institute of Boca Raton Appointed Chief Medical Officer of Cenegenics(R) Medical Institute, Worlds Largest Preventive Age Management Practice
4. Largest RN Union Issues Urgent Call for Nurse Volunteers to Assist Earthquake Ravaged Haiti
5. Long Island Plastic Surgical Practice - the Largest in the U.S. - Opens Virtual Doors on a New, State-of-the-Art Website
6. Anthem Blue Cross Wins Third Largest Medicaid Managed Care Contract Renewal in the Country
7. University of Michigan Health System Receives $15 Million Gift, The Largest Ever for Womens Health
8. Unanimous Vote Creates Largest RN Union in U.S. History
9. The Countrys Largest Cooking Magazine Announces The Comfort Food Diet Cookbook
10. The WFH receives the largest humanitarian aid donation in its history - Donation represents more than 40 million international units to the WFH
11. Kansas City Prepares for Largest Free Health Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... ... May 27, 2017 , ... Most us are familiar with ... new study from the Osteoarthritis Initiative shows that certain people who experience ... this in advance may give doctors the opportunity to treat patients before the problem ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from ... May 30th and 31st at The Four Seasons Hotel Boston. , The ... life sciences, offering exclusive access to key decision makers who influence deal making ...
(Date:5/26/2017)... Clara, Calif. (PRWEB) , ... May 26, 2017 ... ... announces the integration of the CareFusion NOX-T3 portable sleep monitor with its Somnoware ... provides a consistent, browser-based interface for diagnostic device operations. With this platform, initializing ...
(Date:5/26/2017)... ... May 26, 2017 , ... via ... antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper ... thrilled to partner with Cupron® to provide customers with a game changing chair ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... focusing on the Peace Agreements being discussed by President Donald Trump and the rest ... to try to speed up peace talks in the continuous battle between Israel and ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... 2017  A new tight-tolerance microextrusion medical tubing ... materials, is being launched by Natvar, a Tekni-Plex ... in recent years to service a wide variety ... More expensive materials such as glass and fluoropolymers ... to their ability to consistently hold tolerances. This ...
(Date:5/3/2017)... 2017  Kalorama Information notes that transplant diagnostics ... year and this is projected to continue to ... (HSCT) or bone marrow transplants require histocompatibility between ... for this task. This according to a new ... The various PCR-based methodologies, Sanger sequencing and NGS ...
(Date:5/2/2017)... NEW YORK and LONDON ... distributor of market intelligence, MarketResearch.com is pleased to announce ... Consulting AB that allows for the marketing and ... market analyses through the MarketResearch.com website. The ... access to complete product descriptions and tables of contents ...
Breaking Medicine Technology: